子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 光反应性多糖，光交联的多糖产品，其制备方法和从交联多糖制备的医药材料 | CN200580030913.7 | 2005-09-15 | CN101018812A | 2007-08-15 | 佐藤伦也 |
| 一种光反应性多糖，其含有通过共价键与缩水甘油基酯结合的多糖，一种通过使用该光反应性多糖制备的光交联的多糖，和含有该光交联的多糖的医药产品。 | ||||||
| 2 | 醚琥珀酰化羟基聚合物 | CN201410276370.8 | 2006-06-13 | CN104086663A | 2014-10-08 | 斯蒂芬·韦恩·海因茨曼 |
| 本发明提供了醚琥珀酰化羟基聚合物、用于制备醚琥珀酰化羟基聚合物的方法、以及醚琥珀酰化羟基聚合物的用途。 | ||||||
| 3 | 光反应性多糖，光交联的多糖产品，其制备方法和从交联多糖制备的医药材料 | CN200580030913.7 | 2005-09-15 | CN101018812B | 2012-06-13 | 佐藤伦也 |
| 一种光反应性多糖，其含有通过共价键与缩水甘油基酯结合的多糖，一种通过使用该光反应性多糖制备的光交联的多糖，和含有该光交联的多糖的医药产品。 | ||||||
| 4 | 磺基水解酶,其相应的氨基酸序列和核苷酸序列,磺基水解酶制备物,方法及其产物 | CN00810155.8 | 2000-05-09 | CN1362995A | 2002-08-07 | 萨比娜·热尼科; 格哈德·德勒伊特; 伯恩哈德·克洛阿雷; 贝亚·彭尼霍夫; 菲利普·波坦; 奥迪勒·理查德; 布赖恩·鲁道夫 |
| 本发明提供了基于蛋白质总量纯度水平至少为约40wt.%的纯化的磺基水解酶,分离的核酸序列和氨基酸序列,和纯化至少一种磺基水解酶的方法,包括将海藻提取物进行分级分离获得级分;将至少一个级分进行苯基琼脂糖凝胶层析获得含有至少一种磺基水解酶的琼脂糖凝胶级分。本发明还提供了用基于蛋白质总量纯度水平至少为约40wt.%的分离的磺基水解酶修饰的酶促修饰的化合物,以及一种酶促修饰硫酸化的化合物的方法,所述方法包括将至少一种基于蛋白质总量纯度水平至少为约40wt.%的磺基水解酶与硫酸化的化合物形成反应混合物,温育该反应混合物以从硫酸化的化合物中除去硫酸酯基团,形成酶促修饰的化合物。本发明还涉及一种酶促修饰硫酸化的化合物的方法,所述方法包括将第一种磺基水解酶与硫酸化的化合物温育,以从硫酸化的化合物中除去硫酸酯基团,形成中间化合物;接着将第二种磺基水解酶与中间化合物温育,以除去硫酸酯基团,形成酶促修饰的化合物。本发明还提供了一种从海藻中提取nu－和mu－角叉菜聚糖之一的方法,包括:将海藻分散于含有K2CO3的盐溶液中,形成分散液;过滤此分散液获得液体;超滤此分散液以除去盐;浓缩液体;将液体的pH调节为大约8－8.5;从液体中沉淀nu－和mu－角叉菜聚糖之一。 | ||||||
| 5 | 制备从克雷伯氏杆菌中提取的新的半乳聚糖的硫酸酯衍生物的方法 | CN90109783.7 | 1990-12-04 | CN1062171A | 1992-06-24 | 皮埃尔·斯梅斯; 勒内·扎利兹 |
| 一种制备从克雷伯氏杆菌中提取的半乳聚糖硫酸酯衍生物的方法，它包括对从克雷伯氏杆菌中提取的酰基聚糖(主要由约80％中性糖，20％类脂，不到2％的蛋白质组成，分子量为12,500)进行如下处理：缓和酸水解，在阴离子交换柱上高效层析、回收未挂上柱的级份、凝胶过滤、回收含有分子量在4,000—10,000之间的半乳糖的级份，将由此得到的半乳聚糖级份硫酸化，通过透析而纯化，分离所得的半乳聚糖硫酸酯衍生物。 | ||||||
| 6 | BIOFILM INHIBITING COMPOSITION | US13359277 | 2012-01-26 | US20120225098A1 | 2012-09-06 | Jeffrey B. Kaplan; Nataliya V. Balashova; Scott C. Kachlany; Evguenii Vinogradov |
| Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed. | ||||||
| 7 | Processes for making ethersuccinylated hydroxyl polymers | US12850721 | 2010-08-05 | US08049004B2 | 2011-11-01 | Stephen Wayne Heinzman |
| Processes for making ethersuccinylated hydroxyl polymers are provided. | ||||||
| 8 | Polysaccharide produced by microorganism belonging to genus Bifidobacterium | US11993558 | 2006-06-23 | US08022049B2 | 2011-09-20 | Masanori Asada; Mamiko Kohno; Tadashi Kanaya; Tomoe Yoshino; Youichi Matsuura; Yuzo Kawahara; Shinichi Kitamura |
| A polysaccharide comprising galactose, glucose, rhamnose, and pyruvic acid as constituents, wherein the galactose, glucose, and rhamnose are contained in a molar ratio of 4:2:1, and the pyruvic acid is contained in an amount of 4 to 7 wt %. The polysaccharide can be obtained by culturing Bifidobacterium longum JBL05 (NITE BP-82) under anaerobic conditions. | ||||||
| 9 | Novel polysaccharide pro-drug 5-fluorouracil (5-FU) with enhanced target specificity for colorectal cancer and its preparation methods | US11657753 | 2007-09-17 | US20080085871A1 | 2008-04-10 | Joemy Tam; Qi Mei; Li Liu; Qing Wang |
| This invention describes a novel polysaccharide prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for colorectal cancer treatment, and its preparation methods. The prodrug is synthesized by chemically linking anti-cancer drug 5-fluorouracil (5-FU) with a specially selected polysaccharide with molecular weight of 105˜107 Da containing galactose residues. Its distinctive characteristics are that it is a prodrug synthesized by chemically linking polysaccharides with 5-FU through different bridge links for the targeted treatment of colorectal cancer; that the polysaccharides in the chemical compound contain galactose residues; and that these polysaccharides are prepared from natural gums or plant materials. Due to these unique characteristics, as an oral preparation, the polysaccharide component of this novel prodrug can protect the active agent 5-FU from absorption (or metabolism) in the upper gastrointestinal tract and deliver a high concentration of the 5-FU to the colorectal area. Upon reaching the colorectal area, the 5-FU-galactose portion of the prodrug will bind to galectin-3, a-galactoside-binding protein implicated in tumor progression by interactions with its ligands, such as TF (Thomsen-Friedenreich, Galb3GalNAc), Tn (GalNAcaThr/Ser), and Sialy-Tn with galactose residues, which are highly expressed among colorectal cancer cells. Finally, the active 5-FU component will be released locally from the polysaccharide via enzymatic hydrolysis from the local bacterial flora, allowing it to actively kill the colorectal cancer cells. In summary, this novel target-specific prodrug can enhance the selectivity of 5-FU and increase its therapeutic effects in the treatment of colorectal cancer. In addition, with this enhanced target specificity, it is possible to maximize the 5-FU efficacy in cancer patients by having either less toxicity with the same or higher therapeutic dose, and/or administer a lower dosage (if so desired) to achieve the same therapeutic effects, but with much less toxicity. Multiple examples of various approaches to synthesize this novel prodrug are enclosed herein along with several animal model experiments to substantiate the claims as stated above. | ||||||
| 10 | Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers | US11657754 | 2007-09-17 | US20080004237A1 | 2008-01-03 | Joemy Tam; QiBing Mei; Dale Choi |
| This application discloses embodiments of a novel prodrug and its method of synthesis. The prodrug comprises a galactose-containing polysaccharide covalently linked to 5-fluorouracil (5-FU). The galactose residues that are part of the backbone of the galactose-containing polysaccharide mediate the binding between the prodrug and the lectin galectin-3 which is expressed in various cancers. The galactose-containing polysaccharide is isolated from various plant material and covalently bonded to 5-FU. Various formulations (parenteral, or other local or systemic forms) can be used to administer this 5-FU-releasing prodrug to target galectin-3 expressing cancers. | ||||||
| 11 | PHOTOREACTIVE POLYSACCHARIDE, PHOTOCROSSLINKED POLYSACCHARIDE PRODUCT AND METHOD OF MAKING SAME AND MEDICAL MATERIALS MADE FROM THE CROSSLINKED POLYSACCHARIDE | US11162597 | 2005-09-15 | US20060057098A1 | 2006-03-16 | Tomoya Sato |
| A photoreactive polysaccharide which comprises a polysaccharide bound to a glycidyl ester via a covalent bond, a photocrosslinked-polysaccharide prepared by using the photoreactive polysaccharide, and medical products comprising the photocrosslinked-polysaccharide. | ||||||
| 12 | Polysaccharidic esters of retinoic acid | US10483638 | 2004-01-14 | US20040171581A1 | 2004-09-02 | Alessandro Rastrelli; Giuliana Miglierini; Alberto Perbellini; Luca Stucchi |
| The present invention relates to polysaccharidic esters of retinoic acid, wherein the hydroxyl groups of the monosaccharidic units of the polysaccharide are partially or totally esterified with retinoic acid. A process to obtain these esters is also described. The products according to the present invention can be used in the pharmaceutical and cosmetic field. | ||||||
| 13 | Sulfohydrolases, corresponding amino acid and nucleotide sequences, sulfohydrolase preparations, processes, and products thereof | US10626671 | 2003-07-25 | US20040101942A1 | 2004-05-27 | Sabine Genicot; Bernard Kloareg; Phillipe Potin; Brian Rudolph; Gerhard De Ruiter; Bea Penninkhof; Odile Richard |
| A purified sulfohydrolase having a purity level based on total amount of protein of at least about 40 wt %. Isolated nucleic acid sequence and amino acid sequences. A process for purifying at least one sulfohydrolase, including subjecting an extract from seaweed to fractionation to obtain fractions; and subjecting at least one of the fractions to phenyl sepharose chromatography to obtain sepharose fractions containing at least one sulfohydrolase. An enzymatically modified compound which has been modified by an isolated sulfohydrolase having a purity level based on total amount of protein of at least about 40 wt %. A process of enzymatically modifying a sulfated compound, including combining at least one sulfohydrolase, having a purity level based on total amount of protein of at least about 40 wt %, with a sulfated compound form a reaction mixture; and incubating the reaction mixture to remove sulfate groups from the sulfated compound to form an enzymatically modified compound. A process of enzymatically modifying a sulfated compound, including incubating a first sulfohydrolase with a sulfated compound to remove sulfate groups from the sulfated compound to form an intermediate compound; and subsequently incubating the intermediate compound with a second sulfohydrolase to remove sulfate groups to form an enzymatically modified compound. A method for extracting one of nu- and mu-carrageenan from seaweed, including dispersing seaweed in a salt solution including K2CO3 to form a dispersion; filtering the dispersion to obtain a liquid; ultrafiltering the dispersion to remove salts; concentrating the liquid; adjusting the pH of the liquid to about 8 to 8.5; and precipitating one of nu- and mu-carrageenan from the liquid. | ||||||
| 14 | Sulfohydrolases, corresponding amino acid and nucleotide sequences, sulfohydrolase preparations, processes, and products thereof | US09567003 | 2000-05-09 | US06620604B1 | 2003-09-16 | Sabine Genicot; Bernard Kloareg; Phillipe Potin; Brian Rudolph; Gerhard De Ruiter; Bea Penninkhof; Odile Richard |
| A purified sulfohydrolase having a purity level based on total amount of protein of at least about 40 wt %. Isolated nucleic acid sequence and amino acid sequences. A process for purifying at least one sulfohydrolase, including subjecting an extract from seaweed to fractionation to obtain fractions; and subjecting at least one of the fractions to phenyl sepharose chromatography to obtain sepharose fractions containing at least one sulfohydrolase. An enzymatically modified compound which has been modified by an isolated sulfohydrolase having a purity level based on total amount of protein of at least about 40 wt %. A process of enzymatically modifying a sulfated compound, including combining at least one sulfohydrolase, having a purity level based on total amount of protein of at least about 40 wt %, with a sulfated compound form a reaction mixture; and incubating the reaction mixture to remove sulfate groups from the sulfated compound to form an enzymatically modified compound. A process of enzymatically modifying a sulfated compound, including incubating a first sulfohydrolase with a sulfated compound to remove sulfate groups from the sulfated compound to form an intermediate compound; and subsequently incubating the intermediate compound with a second sulfohydrolase to remove sulfate groups to form an enzymatically modified compound. A method for extracting one of nu- and mu-carrageenan from seaweed, including dispersing seaweed in a salt solution including K2CO3 to form a dispersion; filtering the dispersion to obtain a liquid; ultrafiltering the dispersion to remove salts; concentrating the liquid; adjusting the pH of the liquid to about 8 to 8.5; and precipitating one of nu- and mu-carrageenan from the liquid. | ||||||
| 15 | Methods for the extraction of phytochemicals from fibrous plants in the absence of solvent | US571231 | 1995-12-12 | US5756098A | 1998-05-26 | Christopher H. Price; Dale Hedtke; Geoffrey N. Richards; Michael S. Tempesta |
| Methods and apparatus are provided for the recovery of organic compounds from fibrous plant materials. Organic compounds which can be recovered from the fibrous plant materials include plant metabolites, such as arabinogalactan and phenols, which can be isolated from the wood, for example, of the Western Larch and Tamarack tree varieties. In addition to the recovery of organic compounds from wood, fibrous wood products also may be isolated, in the form of a clean fiber that can be used, for example, as raw material in wood processing applications or in the manufacture of high quality paper products. In one embodiment, a fibrous plant material first is compressed, to recover a liquid exudate and a first pressed plant fiber product. Optionally, the fibrous plant material, such as wood particles, is compressed in the substantial absence of any added solvent, to produce a pure normal liquid exudate and a first pressed plant product. The first plant fiber product then may be impregnated with, for example, an aqueous solvent, to recover an extract liquor and impregnated plant fiber. The impregnated plant fiber then is compressed to recover a liquid pressate and a second pressed fiber product. Using these methods, in one embodiment, a substantially pure arabinogalactan exudate and a wood fiber product can be recovered from wood of the genus Larix, with minimal coextraction of phenols. Additionally, a variety of different plant metabolites may be isolated and/or identified from different kinds of woody plants using the methods and apparatus. | ||||||
| 16 | Method of isolating arabinogalactan from larch | US360378 | 1989-06-02 | US4950751A | 1990-08-21 | Jill E. DeWitt |
| An improved method for the extraction of galactans, and especially arabinogalactan, is provided which involves application of sonic energy to a mixture of galactan-containing starting material and extraction medium. Preferably, the method involves providing a mixture of Western larch chips and water, and subjecting this mixture to an acoustic or ultrasonic field for enhancing galactan recovery. | ||||||
| 17 | Preparation of alpha-l-fucosides and l-fucose from fucoidan | US21315562 | 1962-07-30 | US3240775A | 1966-03-15 | SCHWEIGER RICHARD G |
| 18 | Recovery of seaweed mucilage | US79072647 | 1947-12-09 | US2624727A | 1953-01-06 | LE GLOAHEC VICTOR CHARLES EMIL |
| 19 | Manufacture of irish moss | US15629937 | 1937-07-29 | US2231283A | 1941-02-11 | ARNOLD PFISTER |
| 20 | Biofilm inhibiting composition | US13359277 | 2012-01-26 | US08906393B2 | 2014-12-09 | Jeffrey B. Kaplan; Nataliya V. Balashova; Scott C. Kachlany; Evguenii Vinogradov |
| Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed. | ||||||
QQ群二维码
意见反馈
意见反馈